Fibrosis can affect virtually all organs and tissues. In the case of physical or vascular trauma, repairative fibrosis such as wound healing is critical for survival. However, when the fibrotic response becomes dysregulated either as an extended response to injury (e.g. cardiac fibrosis) or as a secondary response to proinflammaory cytokines/growth factors (e.g. cancer stroma) it will result in diseases with devastating pathologies. NovoMedix has developed a platform technology that enables the development of orally available small molecules with wide therapeutic windows to treat fibrotic diseases. The initial targeted indications will be Heart Failure and Triple Negative Breast Cancer (TNBC) with the goal of rapid delivery of this first-in-class therapy to patients.